PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.
PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.
复制标题
DOI:
10.1126/scitranslmed.aba7394
复制
发表时间:
2021-05-26
影响因子:
17.1
通讯作者:
Myeku N
中科院分区:
文献类型:
--
作者:
Schaler AW;Runyan AM;Clelland CL;Sydney EJ;Fowler SL;Figueroa HY;Shioda S;Santa-Maria I;Duff KE;Myeku N
Accumulation of pathological tau in synapses has been identified as an early event in Alzheimer’s disease (AD) and correlates with cognitive decline in patients with AD. Tau is a cytosolic axonal protein, but under disease conditions, tau accumulates in postsynaptic compartments and presynaptic terminals, due to missorting within neurons, transsynaptic transfer between neurons, or a failure of clearance pathways. Using subcellular fractionation of brain tissue from rTg4510 tau transgenic mice with tauopathy and human postmortem brain tissue from patients with AD, we found accumulation of seed-competent tau predominantly in postsynaptic compartments. Tau-mediated toxicity in postsynaptic compartments was exacerbated by impaired proteasome activity detected by measuring lysine-48 polyubiquitination of proteins targeted for proteasomal degradation. To combat the accumulation of tau and proteasome impairment in the postsynaptic compartments of rTg4510 mouse brain, we stimulated the pituitary adenylate cyclase–activating polypeptide (PACAP) type 1 receptor (PAC1R) with its ligand PACAP administered intracerebroventricularly to rTg4510 mice. We observed enhanced synaptic prote- asome activity and reduced total tau in postsynaptic compartments in mouse brain after PACAP treatment. The clearance of tau from postsynaptic compartments correlated with attenuated tauopathy and improved cognitive performance of rTg4510 transgenic mice on two behavioral tests. These results suggest that activating PAC1R could prevent accumulation of aggregate-prone tau and indicate a potential therapeutic approach for AD and other tauopathies.
登录
查看更多内容
影响因子:
4.3
作者:
DeVos SL;Corjuc BT;Oakley DH;Nobuhara CK;Bannon RN;Chase A;Commins C;Gonzalez JA;Dooley PM;Frosch MP;Hyman BT
通讯作者:
Hyman BT
DOI:
10.1186/s10194-018-0855-1
发表时间:
2018-04-04
期刊:
The journal of headache and pain
影响因子:
--
作者:
Hirabayashi T;Nakamachi T;Shioda S
通讯作者:
Shioda S
影响因子:
21.3
作者:
Guo X;Wang X;Wang Z;Banerjee S;Yang J;Huang L;Dixon JE
通讯作者:
Dixon JE
DOI:
10.1084/jem.20160833
发表时间:
2016-11-14
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Guo JL;Narasimhan S;Changolkar L;He Z;Stieber A;Zhang B;Gathagan RJ;Iba M;McBride JD;Trojanowski JQ;Lee VM
通讯作者:
Lee VM
影响因子:
16.2
作者:
Hoover, Brian R.;Reed, Miranda N.;Su, Jianjun;Penrod, Rachel D.;Kotilinek, Linda A.;Grant, Marianne K.;Pitstick, Rose;Carlson, George A.;Lanier, Lorene M.;Yuan, Li-Lian;Ashe, Karen H.;Liao, Dezhi
通讯作者:
Liao, Dezhi